What is controlled for in placebo-controlled trials?

Mayo Clinic Proceedings

Volumn 80, Issue 9, 2005, Pages 1119-1121

  Fillingim, Roger B ^a   Price, Donald D ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; KETOROLAC; MORPHINE; PLACEBO;

ANALGESIA; BEHAVIOR; CHRONIC DAILY HEADACHE; CLINICAL TRIAL; CONDITIONING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; EDITORIAL; EXPECTANCY; HUMAN; MEDICAL LITERATURE; MEMORY; NEUROBIOLOGY; PAIN; PAIN ASSESSMENT; STANDARD; SUGGESTION;

EID: 24144472275     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/80.9.1119     Document Type: Editorial

References (16)

1. Winemiller MH, Billow RG, Laskowski ER, Harmsen WS. Effect of magnetic vs sham-magnetic insoles on nonspecific foot pain in the workplace: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2005; 80:1138-1145.
2. Silberstein SD, Stark SR, Lucas SM, Christie SN, DeGryse RE, Turkel CC, BoNTA-039 Study Group. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2005;80:1126-1137.
3. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. JAMA. 1994; 271:1609-1614.
4. Beecher HK. The powerful placebo. J Am Med Assoc. 1955;159:1602-1606.
5. Harrington A. Introduction. In; Harrington A, ed. The Placebo Effect: An Interdisciplinary Exploration. Cambridge, Mass: Harvard University Press; 1997:1-11.
6. Vase L, Price DD, Verne GN, Robinson ME. The contribution of changes in expected pain, levels and desire for relief to placebo analgesia. In: Price UD, Bushnell MC, eds. Psychological Methods of Pain Control: Basic Science and Clinical Perspectives. Seattle, Wash: IASP Press; 2004:207-232. Progress in Pain Research and Management; vol 29.
7. Montgomery GH, Kirsch I. Classical conditioning and the placebo effect. Pain. 1997;72:107-113.
8. Laska E, Sunshine A. Anticipation of analgesia: a placebo effect. Headache. 1973;13:1-11.
9. Vase L, Robinson ME, Verne GN, Price DD. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients; an empirical investigation. Pain. 2003;105:17-25.
10. Price DD, Milling LS, Kirsch I, Duff A, Montgomery GH, Nicholls SS. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain. 1999;83:147-156.
11. Benedetti F, Arduino C, Amanzio M. Somatotopic activation of opioid systems by target-directed expectations of analgesia. J Neurosci. 1999;19: 3639-3648.
12. Benedetti F, Amanzio M. The neurobiology of placebo analgesia; from endogenous opioids to cholecystokinin. Prog Neurobiol. 1997;52:109-125.
13. Levine JD, Gordon NC, Fields HL. The mechanism of placebo analgesia. Lancet. 1978;2:654-657.
14. Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci. 1999;19:484-494.
15. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? an analysis of clinical trials comparing placebo with no treatment [published correction appears in N Engl J Med. 2001;345:304]. N Engl J Med. 2001;344:1594-1602.
16. Vase L, Riley JL III, Price DD. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain. 2002;99:443-452.